Pneumococcal Vaccine, Polyvalent (23-valent)
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pneumococcal Infection
Conditions
Pneumococcal Infection
Trial Timeline
Oct 1, 2005 → Jan 1, 2006
NCT ID
NCT00496093About Pneumococcal Vaccine, Polyvalent (23-valent)
Pneumococcal Vaccine, Polyvalent (23-valent) is a phase 3 stage product being developed by Merck for Pneumococcal Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT00496093. Target conditions include Pneumococcal Infection.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00496093 | Phase 3 | Completed |
Competing Products
20 competing products in Pneumococcal Infection